The Journal of Pediatrics
Volume 155, Issue 2 , Pages 162-164 , August 2009

Love it or Lev it: Levalbuterol for Severe Acute Asthma—for Now, Leave It

References 

  1. National Asthma Education Program. Expert Panel Report: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1991;
  2. National Asthma Education and Prevention Program. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997;
  3. National Asthma Education and Prevention Program. Expert Panel Report 2: guidelines for the diagnosis and management of asthma: update on selected topics 2002. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002;
  4. National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2007;
  5. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma: United States, 1980-2004. MMWR Surveill Summ. 2007;56:1–54
  6. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma. 2009;46:73–80
  7. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous albuterol versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med. 1993;21:1479–1486
  8. Camargo CA, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev. 2003;(4):CD001115
  9. Dhuper S, Chandra A, Ahmed A, Bisat S, Meghekar A, Verma R, et al. Efficacy and cost comparisons of bronchodilator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma in an inner-city adult population. J Emerg Med. 2008;doi:10.1016/j.jemermed.2008.06.029
  10. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2006;(2):CD000052
  11. Benito-Fernandez J, Gonzalez-Balenciaga M, Capape-Zache S, Vazquez-Ronco MA, Mintegi-Raso S, et al. Salbutamol via metered dose inhaler with spacer versus nebulization for acute treatment of pediatric asthma in the emergency department. Pediatr Emerg Care. 2004;20:656–659
  12. Ploin D, Chapius FR, Stamm D, Robert J, David L, Chatelain PG, et al. High dose albuterol by metered dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double blind, randomized equivalence trial. Pediatrics. 2000;106(2 Pt 1):311–317Erratum in: Pediatrics 2000;106:623
  13. Rodrigo C, Rodrigo G. Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. Am J Emerg Med. 1998;16:637–642
  14. Slattery D, Wong SW, Colin AA. Lev albuterol hydrochloride. Pediatr Pulmonol. 2002;33:151–157
  15. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized lev albuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999;103:615–621
  16. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA Lev albuterol Pediatric Study Group. Low-dose lev albuterol in children with asthma: safety and efficacy in comparison with racemic albuterol. J Allergy Clin Immunol. 2001;108:938–945
  17. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of lev albuterol in 2-5 year-old patients with asthma. Pedatr Pulmonol. 2005;40:477–486
  18. Carl JC, Myers T, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and lev albuterol for treatment of acute asthma. J Pediatr. 2003;143:731–736
  19. Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Lev albuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care. 2005;21:415–419
  20. Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus lev albuterol for the treatment of acute pediatric asthma. Ann Emerg Med. 2005;46:29–36
  21. Ralston ME, Euwema MS, Knecht KR, Ziolowski TJ, Coakley TA, Cline SM. Comparison of lev albuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med. 2005;29:29–35
  22. Andrews TA, McGintee E, Mittal MK, Tyler L, Chew A, Zhang X, et al. High-dose continuous nebulized lev albuterol versus racemic albuterol for pediatric status asthmaticus: a randomized trial. J Pediatr. 2009;155:205–210
  23. Gorelick MH, Stevens MW, Schultz T, Scribano PV. Performance of a novel clinical score, the Pediatric Asthma Assessment Score (PASS), in the evaluation of acute asthma. Acad Emerg Med. 2004;11:10–18
  24. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  25. Elbahlawan L, Binaei S, Christensen ML, Zhang Q, Quasney MW, Dahmer MK. Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006;7:15–18
  26. Carroll CL, Stoltz P, Schramm CM, Zucker AR. β2-Adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest. 2008 Nov 24;doi:10.1378/chest.08-2041

PII: S0022-3476(09)00349-7

doi: 10.1016/j.jpeds.2009.03.062

The Journal of Pediatrics
Volume 155, Issue 2 , Pages 162-164 , August 2009

Article Tools